From the date it became operational in 2006 until 2010, Apeiron pursued projects based on some of Prof. Josef Penninger's research activities.

The recombinant enzyme rhACE2 (APN01), was successfully developed until clinical phase I and then exclusively licensed to GlaxoSmithKline in January 2010.
As a consequence of this deal, Apeiron has invested considerably to broaden its project portfolio with a focus on the field of immuno-oncology.

APN311 (ch14.18/CHO; dinutuximab beta)

APN301 (hu14.18-IL2)


APN401 (Cbl-b)

APN01 (rhACE2)

New Projects